Aclaris Therapeutics, Inc. (ACRS)
Automate Your Wheel Strategy on ACRS
With Tiblio's Option Bot, you can configure your own wheel strategy including ACRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACRS
- Rev/Share 0.1453
- Book/Share 1.1771
- PB 1.2403
- Debt/Equity 0.0
- CurrentRatio 5.0567
- ROIC -0.7973
- MktCap 158090260.0
- FreeCF/Share -0.3935
- PFCF -3.2829
- PE -1.3723
- Debt/Assets 0.0
- DivYield 0
- ROE -0.9241
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ACRS | Wedbush | -- | Outperform | -- | $8 | May 28, 2025 |
| Resumed | ACRS | Cantor Fitzgerald | -- | Overweight | -- | -- | March 18, 2025 |
| Upgrade | ACRS | H.C. Wainwright | Neutral | Buy | -- | $20 | Dec. 23, 2024 |
News
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Published: May 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June.
Read More
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT.
Read More
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.24 per share a year ago.
Read More
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for …
Read More
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.
Read More
About Aclaris Therapeutics, Inc. (ACRS)
- IPO Date 2015-10-06
- Website https://www.aclaristx.com
- Industry Medical - Diagnostics & Research
- CEO Dr. Neal S. Walker D.O., M.D.
- Employees 61